Trusted Resources: Evidence & Education
Scientific literature and patient education texts
A Second Course of Antithyroid Drug Therapy for Recurrent Graves’ Disease: An Experience in Endocrine Practice
source: European Journal of Endocrinology / European Federation of Endocrine Societies
year: 2015
authors: Liu X, Qiang W, Liu X, Liu L, Liu S, Gao A, Gao S, Shi B
summary/abstract:Objective:
There are scarce reports regarding the prognosis of a second course of antithyroid drug (ATD) therapy on recurrent Graves’ disease (GD). The aim of this study was to assess the long-term remission rate after a second ATD therapy and verify significant clinical predictors of a remission.
Design:
A prospective randomized clinical trial with long-term follow-up was conducted to evaluate the effects of a second course of ATD therapy.
Methods:
A total of 128 recurrent GD patients who had finished a first regular ATD therapy were enrolled in this study, and prescribed methimazole (MMI) treatment with titration regimen. The patients were randomly assigned to two groups when the drug doses were reduced to 2.5 mg daily (qd). Group 1 was discontinued with 2.5 mg qd after about 5 months. Group 2 was continuously reduced to 2.5 mg every other day (qod) after 5 months and then discontinued with 2.5 mg qod after about a further 5 months. The patients were followed for 48 months after drug withdrawal.
Results:
Of the total number of patients, 97 cases (75.78%) achieved permanent remission at the end of follow-up, with the recurrence of 31 cases (24.22%). The remission rate of group 2 (84.62%) was significantly higher than that of group 1 (66.67%) (P=0.024). Cox regression showed that the hazard ratio for recurrence decreased under a high or high normal TSH level at drug withdrawal.
Conclusion:
A second course of ATD therapy can bring about a satisfying long-term remission on recurrent GD. The drug dose of 2.5 mg qod and a high or high normal TSH level at drug withdrawal may increase the likelihood of permanent remission.
DOI: 10.1530/EJE-14-0704
read more full text
myBinderRelated Content
-
Comparison of Efficacy and Adverse Effects Between Methimazole 15 Mg+Inorganic Iodine 38 Mg/Day and Methimazole 30 M...Background: Methimazole (MMI) is usuall...
-
Can We Predict Relapse in Graves’ Disease? Results From a Systematic Review and Meta-AnalysisBackground: Identification of pretreatm...
-
FDA Drug Safety Communication: New Boxed Warning on Severe Liver Injury With PropylthiouracilThe United States Food and Drug Administ...
-
Disease Presentation and Remission Rate in Graves’ Disease Treated With Antithyroid Drugs: Is Gender Really a ...Objective: Male gender is considered an...
-
Optimal Iodine Supplementation During Antithyroid Drug Therapy for Graves’ Disease Is Associated With Lower Re...Objective: A relationship between iodin...
-
Methimazole for Graves’ Disease Linked to Acute PancreatitisThe treatment of Graves' disease with th...
-
Antithyroid Drugs (Beyond the Basics)Antithyroid drugs have several benefits ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google